Abstract:Methodology is presented for the synthesis of 6α/β−3-dehydroxynaltrexamines and 6α/β-Nmethyl-3-dehydroxynaltrexamines. A stereoselective route is provided for each target compound while a novel one-pot method for the synthesis of 6α/β−3-N-methyl-3-dehydroxynaltrexamines is also explored. These results enable the versatile and efficient preparation of key epoxymorphinan intermediates to facilitate future selective opioid ligand discovery and development.
“…Eight enantiopure intermediates were required to prepare the target compounds. Part of the protocols to get these essential intermediate amines ( 1–8 ) were made available from previous studies from others and our lab, ,, and a systematic description for all synthetic routes is briefly discussed in the following. For preparing 1–8 , at least one stereoselective synthetic route was adopted and established with reasonable yields.…”
Section: Resultsmentioning
confidence: 99%
“…Additionally, “one-pot” methods were also explored and established as alternative synthetic routes for the four N-methylated intermediate amines (Scheme ). In such approaches, all starting materials were added together and allowed to reflux for 24 h. In both reactions, starting with naltrexone or 3-deydroxynaltrexone, both C6 epimers were generated, while the 6β epimers ( 4 and 8 ) were the major products, respectively.…”
Discovery of analgesics void of abuse liability is critical to battle the opioid crisis in the United States. Among many strategies to achieve this goal, targeting more than one opioid receptor seems promising to minimize this unwanted side effect while achieving a reasonable therapeutic profile. In the process of understanding the structure−activity relationship of nalfurafine, we identified a potential analgesic agent, NMF, as a dual kappa opioid receptor/delta opioid receptor agonist with minimum abuse liability. Further characterizations, including primary in vitro ADMET studies (hERG toxicity, plasma protein binding, permeability, and hepatic metabolism), and in vivo pharmacodynamic and toxicity profiling (time course, abuse liability, tolerance, withdrawal, respiratory depression, body weight, and locomotor activity) further confirmed NMF as a promising drug candidate for future development.
“…Eight enantiopure intermediates were required to prepare the target compounds. Part of the protocols to get these essential intermediate amines ( 1–8 ) were made available from previous studies from others and our lab, ,, and a systematic description for all synthetic routes is briefly discussed in the following. For preparing 1–8 , at least one stereoselective synthetic route was adopted and established with reasonable yields.…”
Section: Resultsmentioning
confidence: 99%
“…Additionally, “one-pot” methods were also explored and established as alternative synthetic routes for the four N-methylated intermediate amines (Scheme ). In such approaches, all starting materials were added together and allowed to reflux for 24 h. In both reactions, starting with naltrexone or 3-deydroxynaltrexone, both C6 epimers were generated, while the 6β epimers ( 4 and 8 ) were the major products, respectively.…”
Discovery of analgesics void of abuse liability is critical to battle the opioid crisis in the United States. Among many strategies to achieve this goal, targeting more than one opioid receptor seems promising to minimize this unwanted side effect while achieving a reasonable therapeutic profile. In the process of understanding the structure−activity relationship of nalfurafine, we identified a potential analgesic agent, NMF, as a dual kappa opioid receptor/delta opioid receptor agonist with minimum abuse liability. Further characterizations, including primary in vitro ADMET studies (hERG toxicity, plasma protein binding, permeability, and hepatic metabolism), and in vivo pharmacodynamic and toxicity profiling (time course, abuse liability, tolerance, withdrawal, respiratory depression, body weight, and locomotor activity) further confirmed NMF as a promising drug candidate for future development.
“…Briefly, 3-dehydroxynaltrexone was first synthesized from naltrexone . Naltrexone and 3-dehydroxynaltrexone were then subjected to four different stereoselective reductive amination methods followed by catalytic hydrogenation under acidic conditions (where applicable) to yield eight different naltrexamines: namely, 6α-naltrexamine, 6α-3-dehydroxynaltrexamine, 6β-naltrexamine, 6β-3-dehydroxynaltrexamine, 6α- N -methyl-naltrexamine, 6α- N -methyl-3-dehydroxynaltrexamine, 6β- N -methyl-naltrexamine, and 6β- N -methyl-3-dehydroxynaltrexamine. − Then primary amines were coupled to carboxylic acids utilizing the EDCI/HOBt coupling reaction while secondary amines were coupled to acyl chlorides under basic conditions. Acyl chlorides were prepared fresh from their carboxylic acid counterparts prior to coupling if they were commercially unavailable .…”
Despite the availability of numerous pain medications, the current array of Food and Drug Administration-approved options falls short in adequately addressing pain states for numerous patients and consequently worsens the opioid crisis. Thus, it is imperative for basic research to develop novel and nonaddictive pain medications. Toward addressing this clinical goal, nalfurafine (NLF) was chosen as a lead and its structure−activity relationship (SAR) systematically studied through design, syntheses, and in vivo characterization of 24 analogues. Two analogues, 21 and 23, showed longer durations of action than NLF in a warm-water tail immersion assay, produced in vivo effects primarily mediated by KOR and DOR, penetrated the blood−brain barrier, and did not function as reinforcers. Additionally, 21 produced fewer sedative effects than NLF. Taken together, these results aid the understanding of NLF SAR and provide insights for future endeavors in developing novel nonaddictive therapeutics to treat pain.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.